文献速递头颈部肿瘤放疗放疗物理与技术

FDG-PET/CT与剂量学数据相关性:头颈癌放疗后复发模式分析

Correlation of [18F] FDG-PET/CT with dosimetry data: recurrence pattern after radiotherapy for head and neck carcinoma.
PubMed 文献 · Radiat Oncol · 2021-03-21

本研究分析87例接受根治性放化疗的头颈鳞癌患者,治疗前FDG-PET/CT定义的代谢靶体积与复发时PET代谢体积对照,发现复发多起源于治疗前高FDG信号区域,50%复发为野内复发,提示对这些高信号体积进行剂量强化值得进一步评估。

要点

  • 87例头颈鳞癌根治性放化疗患者中,10例(11.5%)出现原发部位复发。
  • 复发多位于治疗前FDG高摄取体积内,50%为野内复发、40%为边缘复发、10%为野外复发。
  • 复发体积与治疗前代谢靶体积重叠区域D99平均68.1 Gy(处方剂量70 Gy),提示高剂量区仍可复发。

核心结论

  • 头颈鳞癌根治性放化疗后复发可能起源于治疗前FDG信号最高的体积,高剂量体积内复发支持对这些体积进行剂量强化值得进一步评估。

研究设计与样本

  • 2012至2016年纳入87例接受根治性放化疗的头颈鳞癌患者,均行治疗前FDG-PET/CT及MRI/CT放疗定位。
  • 对出现局部复发的患者于发现复发时行FDG-PET/CT,用自适应阈值算法分割代谢靶体积。
  • 生成治疗前与复发代谢靶体积的重叠体积,在计划CT上以D99和D95评估剂量覆盖。

主要发现

  • 87例中10例(11.5%)出现原发部位复发。
  • 治疗前代谢靶体积平均12.2 cc(范围4.6-28.9 cc),复发代谢靶体积平均4.3 cc(范围1.1-12.7 cc)。
  • 2例复发100%位于治疗前代谢靶体积内,4例大部分位于其内(61-91%),4例位于其边缘(1-33%)。
  • 剂量学分析显示5例(50%)为野内复发,4例(40%)为边缘复发,1例(10%)为野外复发。
  • 重叠体积D99平均68.1 Gy(范围66.5-69.2 Gy),处方剂量为70 Gy。

关键数值与推荐

  • 复发体积定义:D95≥95%处方剂量为野内复发,D95在95%至20%之间为边缘复发,D95<20%为野外复发。

临床怎么用

  • 治疗前FDG高摄取体积是局部复发的高危区域,可考虑作为剂量强化的靶区加以进一步研究。
  • 复发时FDG-PET/CT与治疗前PET对照有助于区分野内、边缘和野外复发,辅助评估剂量覆盖。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyze the pattern of failure in relation to pre-treatment [18F] FDG-PET/CT uptake in head and neck squamous cell carcinoma (HNSCC) patients treated with definitive radio-chemotherapy (RT-CHT). METHODS AND MATERIALS: From 2012 to 2016, 87 HNSCC patients treated with definitive RT-CHT, with intensity modulated radiation therapy with simultaneous integrated boost, underwent pre-treatment [18F] FDG-PET/CT (PETpre), and MRI/CT for radiotherapy (RT) planning purposes. Patients with local recurrence, received [18F] FDG-PET/CT, (PETrec) at the time of the discovery of recurrence. In these patients, the metabolic target volume (MTV), MTVpre and MTVrec were segmented on PET images by means of an adaptive thresholding algorithm. The overlapping volume between MTVpre and MTVrec (MTVpre&rec) was generated and the dose coverage of MTVrec and MTVpre&rec was checked on the planning CT using the D99 and D95 dose metrics. The recurrent volume was defined as: ''In-Field (IF)'', "Marginal recurrence" or ''Out-of-Field (OF)'' if D95 was respectively equal or higher than 95%, D95 was between 95 and 20% or the D95 was less than 20% of prescribed dose. RESULTS: We found 10/87 patients (11.5%) who had recurrence at primary site. Mean MTVpre was 12.2 cc (4.6-28.9 cc), while the mean MTVrec was 4.3 cc (1.1-12.7 cc). Two recurrences resulted 100% inside MTVpre, 4 recurrences were mostly inside (61-91%) and 4 recurrences were marginal to MTVpre (1-33%). At dosimetric analysis, five recurrences (50%) were IF, 4 (40%) marginal and one (10%) OF. The mean D99 of the overlapping volumes MTVpre&rec was 68.1 Gy (66.5-69.2 Gy), considering a prescription dose of 70 Gy to the planning target volume (PTV). CONCLUSION: Our study shows that the recurrence may originate from the volume with the highest FDG-signal. Tumor relapse in the high-dose volume support the hypothesis that an intensification of the dose on these volumes could be further assessed to prevent local relapse.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Pisani C, Vigna L, Mastroleo F, et al. Correlation of [18F] FDG-PET/CT with dosimetry data: recurrence pattern after radiotherapy for head and neck carcinoma. Radiat Oncol. 2021. PMID: 33743759. doi:10.1186/s13014-021-01787-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。